Nutrition Interventions for Chronic Liver Diseases and Nonalcoholic Fatty Liver Disease

Medical Clinics of North America

Volumn 100, Issue 6, 2016, Pages 1303-1327

  Pimentel, Carolina Frade Magalhaes Girardin ^a   Lai, Michelle ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Diet; Lifestyle intervention; Liver cirrhosis; Liver disease; Nonalcoholic liver disease; Nutrition

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC LIVER DISEASE; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DIET THERAPY; DIETARY COMPLIANCE; DIETARY FIBER; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LOW CARBOHYDRATE DIET; LOW FAT DIET; MALNUTRITION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; NUTRITIONAL DEFICIENCY; OBESITY; OVERNUTRITION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; WEIGHT LOSS PROGRAM; CHRONIC DISEASE; COMPLICATION; DIET; LIFESTYLE; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; WEIGHT REDUCTION;

CHRONIC DISEASE; DIET; HUMANS; LIFE STYLE; LIVER CIRRHOSIS; MALNUTRITION; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITION ASSESSMENT; WEIGHT LOSS;

EID: 84994854352     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2016.06.010     Document Type: Review

References (94)

1. 1 Mokdad, A.A., Lopez, A.D., Shahraz, S., et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med, 12(1), 2014, 145.
2. 2 Lozano, R., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2095–2128.
3. 3 Rinella, M.E., Nonalcoholic fatty liver disease. JAMA, 313(22), 2015, 2263.
4. 4 Lautz, H., Selberg, O., Korber, J., et al. Protein calorie malnutrition in liver cirrhosis. Clin Investig 70:6 (1992), 478–486.
5. 5 DiCecco, S., Wieners, E., Wiesner, R., et al. Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc 64:1 (1989), 95–102.
6. 6 Bellentani, S., Scaglioni, F., Marino, M., et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28:1 (2010), 155–161.
7. 7 Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:1 (2011), 124–131.
8. 8 Mozundar, A., Liguori, G., Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 34:1 (2011), 1–4.
9. 9 Barrera, F., George, J., The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis 18:1 (2014), 91–112.
10. 10 Anty, R., Iannelli, A., Patouraux, S., et al. Alimentary pharmacology and therapeutics a new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 32 (2010), 1315–1322.
11. 11 Adams, L.A., Sanderson, S., Lindor, K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:1 (2005), 132–138.
12. 12 Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:5 (2010), 1820–1832.
13. 13 Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59:6 (2014), 2188–2195.
14. 14 Ong, J.P., Younossi, Z.M., Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 11:1 (2007), 1–16.
15. 15 Finucane, M.M., Stevens, G.A., Cowan, M.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 377:9765 (2011), 557–567.
16. 16 World Health Organization, Obesity and overweight. 2014, World Health Organization, Geneva (Switzerland), 311 Available at: http://www.who.int/mediacentre/factsheets/fs311/en/http://www.who.int/mediacentre/factsheets/fs311/en/.
17. 17 Ferolla, S.M., Dietary approach in the treatment of nonalcoholic fatty liver disease. World J Hepatol, 7(24), 2015, 2522.
18. 18 Swinburn, B.A., Sacks, G., Hall, K.D., et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:9793 (2011), 804–814.
19. 19 Fontaine, K.R., Redden, D.T., Wang, C., et al. Years of life lost due to obesity. J Am Med Assoc 289:2 (2003), 187–193.
20. 20 Milić, S., Lulić, D., Stimac, D., Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol 20:28 (2014), 9330–9337.
21. 21 Welzel, T.M., Graubard, B.I., Zeuzem, S., et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54:2 (2011), 463–471.
22. 22 Bechmann, L.P., Hannivoort, R.A., Gerken, G., et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56:4 (2012), 952–964.
23. 23 Purnak, T., Yilmaz, Y., Liver disease and malnutrition. Best Pract Res Clin Gastroenterol 27:4 (2013), 619–629.
24. 24 Asrih, M., Jornayvaz, F.R., Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr 33:2 (2014), 186–190.
25. 25 Musso, G., Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:4 (2003), 909–916.
26. 26 Ouyang, X., Cirillo, P., Sautin, Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48:6 (2008), 993–999.
27. 27 Carter-Kent, C., Zein, N.N., Feldstein, A.E., Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 103:21 (2008), 1036–1042.
28. 28 Xu, A., Wang, Y., Keshaw, H., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:1 (2003), 91–100.
29. 29 Postic, C., Girard, J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118:3 (2008), 829–838.
30. 30 Assy, N., Nassar, F., Nasser, G., et al. Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol 15:15 (2009), 1809–1815.
31. 31 Neuschwander-Tetri, B.A., Carbohydrate intake and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 16:4 (2013), 446–452.
32. 32 Roglans, N., Vilà, L., Farré, M., et al. Impairment of hepatic STAT-3 activation and reduction of PPARα activity in fructose-fed rats. Hepatology 45:3 (2007), 778–788.
33. 33 Wei, Y., Wang, D., Topczewski, F., et al. Fructose-mediated stress signaling in the liver: implications for hepatic insulin resistance. J Nutr Biochem 18:1 (2007), 1–9.
34. 34 Liu, S., Willett, W.C., Stampfer, M.J., et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women 1–3. Am J Clin Nutr 71 (2000), 1455–1461.
35. 35 Hu, Y., Block, G., Norkus, E.P., et al. Relations of glycemic index and glycemic load with plasma oxidative stress markers. Am J Clin Nutr 84:1 (2006), 70–77.
36. 36 Liou, I.W., Management of end-stage liver disease. Med Clin North Am 98:1 (2014), 119–152.
37. 37 Ginés, P., Quintero, E., Arroyo, V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 7:1 (1987), 122–128.
38. 38 Manne, V., Saab, S., Impact of nutrition and obesity on chronic liver disease. Clin Liver Dis 18:1 (2014), 205–218.
39. 39 Runyon, B.A., Management of adult patients with ascites due to cirrhosis: an update. Hepatology 49:6 (2009), 2087–2107.
40. 40 Ueno, T., Sugawara, H., Sujaku, K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepathol 27:16 (1997), 103–107.
41. 41 Harrison, S.A., Fecht, W., Brunt, E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:1 (2009), 80–86.
42. 42 Tapper, E.B., Sengupta, N., Hunink, M.G.M., et al. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol 110:9 (2015), 1298–1304.
43. 43 Tapper, E., Lai, M., Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study. Hepatology 63 (2016), 1184–1189.
44. 44 Montano-Loza, A.J., Muscle wasting: a nutritional criterion to prioritize patients for liver transplantation. Curr Opin Clin Nutr Metab Care 17:3 (2014), 219–225.
45. 45 Durand, F., Buyse, S., Francoz, C., et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 60:6 (2014), 1151–1157.
46. 46 Collins, S., Using middle upper arm circumference to assess severe adult malnutrition during famine. JAMA 276:5 (1996), 391–395.
47. 47 Detsky, A., McLaughlin, J., Baker, J., et al. What is Subjective Global Assessment of nutritional status?. Nutr Hosp 23:4 (2008), 400–407.
48. 48 Álvares-da-Silva, M.R., Reverbel da Silveira, T., Comparison between handgrip strength, Subjective Global Assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 21 (2005), 113–117.
49. 49 Huang, M.A., Greenson, J.K., Chao, C., et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100:5 (2005), 1072–1081.
50. 50 Keating, S.E., Hackett, D.A., George, J., et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 57:1 (2012), 157–166.
51. 51 Chavez-Tapia, N.C., Tellez-Avila, F.I., Barrientos-Gutierrez, T., et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev(1), 2010 CD007340.
52. 52 Anese, M., Nicoli, M.C., Antioxidant properties of ready-to-drink coffee brews. J Agric Food Chem 51 (2003), 942–946.
53. 53 Murase, T., Misawa, K., Minegishi, Y., et al. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. Am J Physiol Endocrinol Metab 300:1 (2011), E122–E133.
54. 54 Anty, R., Marjoux, S., Iannelli, A., et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 57:5 (2012), 1090–1096.
55. 55 Molloy, J.W., Calcagno, C.J., Williams, C.D., et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55:2 (2012), 429–436.
56. 56 Birerdinc, A., Stepanova, M., Pawloski, L., et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 35:1 (2012), 76–82.
57. 57 Bozzeto, L., Prinster, A., Costagliola, L., et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 35 (2012), 1429–1435.
58. 58 Ryan, M.C., Itsiopoulos, C., Thodis, T., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59:1 (2013), 138–143.
59. 59 Joensen, A.M., Overvad, K., Dethlefsen, C., et al. Marine n-3 polyunsaturated fatty acids in adipose tissue and the risk of acute coronary syndrome. Circulation 124:11 (2011), 1232–1238.
60. 60 Sawada, N., Inoue, M., Iwasaki, M., et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 142:7 (2012), 1468–1475.
61. 61 Parker, H.M., Johnson, N.A., Burdon, C.A., et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56:4 (2012), 944–951.
62. 62 Papathanasopoulos, A., Camilleri, M., Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. Gastroenterology 138:1 (2010), 65–72.e1-2.
63. 63 Ye, E., Chacko, S., Chou, E., et al. Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. J Nutr 142:7 (2012), 1304–1313.
64. 64 Abdelmalek, M.F., Sanderson, S.O., Angulo, P., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50 (2009), 1818–1826.
65. 65 Koeth, R.A., Wang, Z., Levison, B.S., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19:5 (2013), 576–585.
66. 66 Utzschneider, K.M., Bayer-Carter, J.L., Arbuckle, M.D., et al. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr 109:6 (2013), 1096–1104.
67. 67 van der Meer, R.W., Hammer, S., Lamb, H.J., et al. Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab 93:7 (2008), 2702–2708.
68. 68 Westerbacka, J., Lammi, K., Häkkinen, A.M., et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 90:5 (2005), 2804–2809.
69. 69 Kontogianni, M.D., Tileli, N., Margariti, A., et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr 33 (2014), 678–683.
70. 70 de Luis, D., Izaola, A., Sagrado, M., et al. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Hepatology 53:1 (2012), 730–735.
71. 71 Haufe, S., Engeli, S., Kast, P., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53:5 (2011), 1504–1514.
72. 72 Ryan, M.C., Abbasi, F., Lamendola, C., et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 30:5 (2007), 1075–1080.
73. 73 Tendler, D., Lin, S., Yancy, W.S., et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 52:2 (2007), 589–593.
74. 74 Promrat, K., Kleiner, D.E., Niemeier, H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:1 (2010), 121–129.
75. 75 Rodríguez-Hernández, H., Cervantes-Huerta, M., Rodríguez-Moran, M., et al. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Ann Hepatol 10:4 (2011), 486–492.
76. 76 Elias, M.C., Parise, E.R., de Carvalho, L., et al. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 26 (2010), 1094–1099.
77. 77 Lin, W.-Y., Wu, C.-H., Chu, N.-F., et al. Efficacy and safety of very-low-calorie diet in Taiwanese: a multicenter randomized, controlled trial. Nutrition 25:11–12 (2009), 1129–1136.
78. 78 Razavi Zade, M., Telkabadi, M.H., Bahmani, F., et al. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. Liver Int 36 (2016), 563–571.
79. 79 Sanyal, A.J., Chalasani, N., Kowdley, K., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:18 (2010), 1675–1685.
80. 80 Bjelakovic, G., Nikolova, D., Gluud, L., et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention systematic review and meta-analysis. JAMA 297:8 (2007), 842–857.
81. 81 Ahmed, A., Wong, R.J., Harrison, S.A., Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 13:12 (2015), 2062–2070.
82. 82 Harrison, S., Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:11 (2003), 2485–2490.
83. 83 Targher, G., Bertolini, L., Scala, L., et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17:7 (2007), 517–524.
84. 84 Kwok, R.M., Torres, D.M., Harrison, S.A., Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?. Hepatology 58 (2013), 1166–1174.
85. 85 Merli, M., Riggio, O., Romiti, A., et al. Basal energy production rate and substrate use in stable cirrhotic patients. Hepatology 12:1 (1990), 106–112.
86. 86 Muller, M., Boker, K., Selberg, O., Are patients with liver cirrhosis hypermetabolic?. Clin Nutr 13:3 (1994), 131–144.
87. 87 Johnson, T.M., Overgard, E.B., Cohen, A.E., et al. Nutrition assessment and management in advanced liver disease. Nutr Clin Pract 28:1 (2013), 15–29.
88. 88 Toshikuni, N., Arisawa, T., Tsutsumi, M., Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol 20:23 (2014), 7286–7297.
89. 89 Kachaamy, T., Bajaj, J.S., Diet and cognition in chronic liver disease. Curr Opin Gastroenterol 27 (2011), 174–179.
90. 90 Fialla, A.D., Israelsen, M., Hamberg, O., et al. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int 35:9 (2015), 2072–2078.
91. 91 Douketis, J.D., Macie, C., Thabane, L., et al. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes 29:10 (2005), 1153–1167.
92. 92 St George, A., Bauman, A., Johnston, A., et al. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol 24 (2009), 399–407.
93. 93 Stewart, K.E., Levenson, J.L., Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease. Clin Liver Dis 16:3 (2012), 615–629.
94. 94 Haskell, W.L., Lee, I., Pate, R.R., et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 116:9 (2007), 1081–1093.